AAM
ESPR

Alpine Associates Management’s Esperion Therapeutics ESPR Stock Holding History

Alpine Associates Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.74M Buy
+1,500,000
New +$4.2M 0.3% 57

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $490M AUM 21.68% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Alpine Associates Management's ESPR Position: Q2 2026 in Review

Alpine Associates Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 1,500,000 shares worth $4.74M. The stake represents 0.3% of the portfolio and ranks #57 among its holdings.

67 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Alpine Associates Management held 1,500,000 shares of Esperion Therapeutics worth $4.74M as of Q2 2026.
  • Esperion Therapeutics was a new Alpine Associates Management position in Q2 2026.
  • Esperion Therapeutics made up 0.3% of Alpine Associates Management's portfolio in Q2 2026, its #57 holding.
  • 67 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Alpine Associates Management's 13F filing for Q2 2026, filed 6 Aug 2026.